Shots:
- Antares Therapeutics has entered into a strategic collaboration with Novartis to discover, develop & commercialize small molecule therapies against undruggable oncology targets
- Antares will lead research & apply its discovery engine to a select number of historically undruggable targets until option exercise, while continuing to advance its wholly owned & partnered precision medicine pipeline in cancer & other serious diseases
- As per the deal, Antares will receive a $105M upfront & ~$1.8B in additional payments across programs, incl. option exercise fees, development, regulatory, & commercial milestones, with tiered royalties on global net sales up to the low double-digits
Ref: Businesswire | Image: Antares & Novartis | Press Release
Related News: Novartis Inks a ~$1.44B Deal with Orionis to Advance Molecular Glue Therapies for Multiple Targets
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
